A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.

doi:10.1136/bcr-2017-219770

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.

BMJ case reports - 4 Jun 2018

Niwa Hideyuki, Nakahara Yoshiro, Sasaki Jiichiro, Masuda Noriyuki

Abstract excerpt

Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV lung adenocarcinoma with an uncommon EGFR mutation in exon 21 (L861Q). The disease progressed 2 years after he...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Piperazines

Share to Positron Emission Tomography Computed Tomography

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 29866661
DOI: 10.1136/bcr-2017-219770
PMCID: PMC5990104

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.